2.06
-0.13 (-5.72%)
| Penutupan Terdahulu | 2.19 |
| Buka | 2.16 |
| Jumlah Dagangan | 6,780,512 |
| Purata Dagangan (3B) | 2,953,788 |
| Modal Pasaran | 251,746,416 |
| Harga / Jualan (P/S) | 1.73 |
| Harga / Buku (P/B) | 5.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 2 Aug 2023 - 7 Aug 2023 |
| Margin Keuntungan | 46.54% |
| Margin Operasi (TTM) | -32.78% |
| EPS Cair (TTM) | 2.11 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 340.14% |
| Nisbah Semasa (MRQ) | 3.70 |
| Aliran Tunai Operasi (OCF TTM) | -109.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -78.01 M |
| Pulangan Atas Aset (ROA TTM) | -58.61% |
| Pulangan Atas Ekuiti (ROE TTM) | 121.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | X4 Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -1.5 |
| Purata | 0.63 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.43% |
| % Dimiliki oleh Institusi | 55.70% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Stifel, 385.44%) | Beli |
| Median | 7.50 (264.08%) | |
| Rendah | 5.00 (HC Wainwright & Co., 142.72%) | Beli |
| Purata | 7.50 (264.08%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.72 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 05 Dec 2025 | 10.00 (385.44%) | Beli | 3.80 |
| HC Wainwright & Co. | 10 Nov 2025 | 5.00 (142.72%) | Beli | 3.63 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Nov 2025 | Pengumuman | X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference |
| 05 Nov 2025 | Pengumuman | X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 27 Oct 2025 | Pengumuman | X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million |
| 24 Oct 2025 | Pengumuman | X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering |
| 23 Oct 2025 | Pengumuman | X4 Pharmaceuticals Announces Proposed Underwritten Public Offering |
| 17 Sep 2025 | Pengumuman | X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |